Research Appraisalother

In silico discovery and biological evaluation of a novel selective HDAC8 inhibitor featuring 1H-pyrazolo[3,4-b]pyridine scaffold

Bioorganic chemistryYan, Wenying, Shi, He, Li, Tingting et al.5 June 2026DOI

Clinical Snapshot

75CEBM

Evidence: Weakother

PICO Framework

P — Population	HCT116 colorectal cancer cell line and HDAC8 enzyme
I — Intervention	Novel compound Cmpd.16 with 1H-pyrazolo[3,4-b]pyridine scaffold
C — Comparator	Control conditions and other HDAC isoforms for selectivity assessment
O — Outcomes	HDAC8 inhibitory activity (IC50), cell proliferation inhibition, apoptosis induction, cell cycle arrest

Bottom Line

This preclinical study reports the discovery of Cmpd.16, a novel HDAC8 inhibitor with promising potency (IC50 = 0.16 μM) identified through computational screening. While the compound demonstrates selective HDAC8 inhibition and induces apoptosis in colorectal cancer cells, this represents very early-stage drug discovery research. The study's strength lies in its innovative computational approach and multi-modal validation, but significant limitations include testing in only one cell line, incomplete selectivity profiling, and absence of in vivo data. Clinical translation would require extensive further development including comprehensive safety studies, animal testing, and clinical trials. For practicing oncologists, this work contributes to the growing understanding of HDAC8 as a therapeutic target but has no immediate clinical implications. The research may inform future drug development efforts in epigenetic cancer therapy.

Evidence: Weak

Key Findings

P Value: Not reported
Effect Size: IC50 = 0.16 ± 0.01 μM
Primary Outcome: HDAC8 inhibitory activity
Nnt Or Sensitivity: Moderate HCT116 cell growth inhibition with apoptosis induction and G2/M arrest
Confidence Interval: Not reported

Clinical Application

Very low - early preclinical stage requiring extensive development Would require TGA approval pathway for novel chemical entities; potential relevance to Australian cancer research priorities but years from clinical application Patients with HDAC8-overexpressing malignancies, particularly colorectal cancer

Abstract

Histone deacetylase 8 (HDAC8), a pivotal epigenetic regulator orchestrating chromatin remodeling and transcriptional control, has emerged as a compelling anticancer target owing to its frequent dysregulation in malignancies. The development of isoform-selective inhibitors, however, confronts substantial challenges because of the pronounced structural conservation across HDAC isoforms. This study developed a high-efficiency drug screening pipeline primarily leveraging artificial learning (AI) models and molecular simulation techniques, and further evaluated the biological activity of computationally prioritized compounds through enzymatic inhibition assays and cellular experiments. The structurally novel compound Cmpd.16 was successfully identified, exhibiting promising inhibitory activity against HDAC8 (IC50 = 0.16 ± 0.01 μM) and moderately inhibited HCT116 cell proliferation mainly through the induction of apoptosis and G2/M phase cell cycle arrest. Subsequently, molecular dynamics simulations were employed to investigate the binding conformation of Cmpd.16 within the active pocket, and the key residues identified through free energy decomposition further elucidated the drug-target binding mode. Collectively, Cmpd.16, featuring 1H-pyrazolo[3,4-b]pyridine scaffold, was discovered via an efficient screening workflow, offering valuable insights to guide the rational design of HDAC8-targeted agents.

References

1.Yan, W., Shi, H., Li, T., Fu, Y., Zhang, Y., Zhang, Y., Liu, J., & Li, X. (2026). In silico discovery and biological evaluation of a novel selective HDAC8 inhibitor featuring 1H-pyrazolo[3,4-b]pyridine scaffold. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109660

Share:X LinkedIn

Related Research

Systematic Review

15CEBM

Cancer medicine

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

1 Aug 2026

other

65CEBM

Acta oncologica (Stockholm, Sweden)

User perceptions of machine learning models as decision support for colorectal cancer multidisciplinary team conferences (AID-SIM-2): a qualitative simulation study.